⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27468149 | 0.81 | — | — | |
| SCHEMBL21331736 | 0.72 | — | — | |
| SCHEMBL5707703 | 0.61 | — | — | |
| SCHEMBL902017 | 0.59 | — | — | |
| SCHEMBL669547 | 0.57 | — | — | |
| SCHEMBL8738119 | 0.54 | — | — | |
| SCHEMBL4397549 | 0.54 | — | — | |
| SCHEMBL2166227 | 0.48 | — | — | |
| SCHEMBL2166234 | 0.48 | — | — | |
| SCHEMBL29664 | 0.46 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102886-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-16 | — | — | WO | claimed |
| US-10266542-B2 | EZH2 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-04-23 | — | — | US | claimed |
| US-20180265517-A1 | EZH2 Inhibitors | Mirati Therapeutics, Inc. | 2018-09-20 | — | — | US | claimed |
| EP-3057948-B1 | SELECTIVELY SUBSTITUTED QUINOLINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-03-14 | — | — | EP | claimed |
| US-9663486-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-05-30 | — | — | US | claimed |
| EP-3057948-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | claimed |
| US-20160176841-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-06-23 | — | — | US | claimed |
| EP-2721008-B1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES AS P53 (MDM2 OR MDM4) INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | claimed |
| WO-2015057655-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | claimed |
| US-8859535-B2 | Hydroxy substituted isoquinolinone derivatives | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | claimed |
| WO-2012175520-A1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | claimed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | claimed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | claimed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | claimed |
| EP-2185537-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2010-05-19 | — | — | EP | claimed |
| WO-2009016498-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-6884868-B1 | Cyclic hexapeptides having antibiotic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | claimed |
| EP-1173472-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-23 | — | — | EP | claimed |
| WO-2000064927-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | WO | claimed |